Effect of valproic acid on miRNAs affecting histone deacetylase in a model of anaplastic thyroid cancer

• DOI: 10.1007/s11033-021-06616-2
• Publication Date: 2021-08-10T09:55:11Z
• Authors: Nur Selvi Gunel; Nihal Birden; Cansu Caliskan Kurt; Bakiye Goker Bagca; Behrouz Shademan; Fatma Sogutlu; Neslihan Pinar Oz...; Cigir Biray Avci
• Keywords: Anaplastic thyroid cancer; Histone deacetylase inhibitor; Valproic Acid

Abstract Thyroid cancer is the most common malignant tumor of the endocrine system seen in the thyroid gland. More than 90% of thyroid cancers comprise papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Although anaplastic thyroid carcinoma (ATC) accounts for less than 2% of thyroid cancer. But patients' lifespan after diagnosis is about 6 months. Surgical interventions, radioactive iodine use, and chemotherapy are not sufficient in the treatment of ATC, so alternative therapies are needed. The WST-1 assay test was performed to evaluate the anti-proliferative effects of Valproic acid (VPA). Also, Effect of VPA on miRNAs affecting histone deacetylase were determined by Quantitative RT-PCR. In BRAFV600E / mut SW1736 (SW1736) cell line IC50 dose for VPA found 1.6 mg/ml. in our study, the level of oncogenic genes expression in cells treated with VPA, including miR-184, miR-222-5p, miR-124-3p, and miR-328-3p, decreased. Also, the expression of tumor inhibitory genes is miR-323-5p, miR-182-5p, miR-138-5p, miR-217, miR-15a-5p, miR-29b-3p, miR-324-5p and miR-101- 5p increased significantly. VPA can ad-just countless gene expression patterns, including microRNAs (miRNAs), by targeting histone deacetylase (HDAC). We got very promising results with VPA.